We studied the ability of lymphokine-activated killer cells to lyse A549 human non-small cell lung cancer cells after preincubation with cisplatin. Lymphokine-activated killer cells obtained after incubation of human blood lymphocytes with interleukin-2 were characterized by high expression of natural killer cell antigens and activation molecules. Lymphokine-activated killer cells produced potent cytotoxic effect on intact A549 cells and lysed tumor cells survived after treatment with cisplatin in concentrations of IC50 and IC30. Cisplatin in noncytotoxic concentrations did not increase lytic activity of lymphokine-activated killer cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-007-0297-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The future of cellular therapy for the treatment of renal cell carcinoma.
Expert Opin Biol Ther
November 2024
Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Introduction: Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have entered the clinical arena. Adoptive cell immunotherapies have recently revolutionized the treatment of cancer and hold the promise to further advance the treatment of RCC.
Areas Covered: In this review, we summarize the latest preclinical and clinical development in the field of adoptive cell immunotherapy for the treatment of RCC, focusing on lymphokine-activated killer (LAK) cells, cytokine-induced killer (CIK) cells, tumor-infiltrating T cells (TILs), TCR-engineered T cells, chimeric antigen receptor (CAR) T cells, and dendritic cell vaccination strategies.
[Research progress of tumor-infiltrating lymphocytes in malignant hematological diseases].
Zhonghua Xue Ye Xue Za Zhi
June 2024
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
In recent years, immunotherapy has been progressing rapidly in tumor treatment, among which, adoptive immunotherapy of immunologically active cells has also gained increasing attention in the treatment of malignant hematological diseases. Tumor-infiltrating lymphocytes are a heterogeneous class of T-cell-based lymphocytes with high heterogeneity. As an important component of the tumor microenvironment, TILs are crucial in the development of malignant tumors.
View Article and Find Full Text PDFTOPK Inhibition Enhances the Sensitivity of Colorectal Cancer Cells to Radiotherapy by Reducing the DNA Damage Response.
Curr Med Sci
June 2024
Translational Medical Center, Huaihe Hospital, Henan University, Kaifeng, 475000, China.
Objective: Abnormal expression of T-lymphokine-activated killer cell-originated protein kinase (TOPK) was reported to be closely related to the resistance of prostate cancer to radiotherapy and to targeted drug resistance in lung cancer. However, the role of TOPK inhibition in enhancing radiosensitivity of colorectal cancer (CRC) cells is unclear. This study aimed to evaluate the radiosensitization of TOPK knockdown in CRC cells.
View Article and Find Full Text PDFEvolution of cell therapy for renal cell carcinoma.
Mol Cancer
January 2024
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies. However, curative treatment, particularly for advanced-stage disease, remains rare. Cell therapy as a "living drug" has achieved hematological malignancy cures with a high response rate, and significant research efforts have been made to facilitate its translation to solid tumors.
View Article and Find Full Text PDFTOPK promotes the development of psoriasis and worenine alleviates psoriasiform dermatitis by inhibiting TOPK activity.
J Eur Acad Dermatol Venereol
May 2024
Translational Medical Center, Huaihe Hospital, Henan University, Kaifeng, Henan, China.
Background: Psoriasis is an inflammatory skin disease. The pathogenesis of psoriasis has not been fully elucidated. T-lymphokine-activated killer cell-originated protein kinase (TOPK) activity increases in a proinflammatory environment, and inhibiting TOPK blocks inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!